Can you take Chlorambucil with Velsipity?

Chlorambucil has a major potential interaction with Bleeding Disorder.

Chlorambucil can severely suppress bone marrow function. It induces a slowly progressive lymphopenia and dose-related neutropenia. Thrombocytopenia and anemia may also occur. Irreversible bone marrow suppression has been reported and is associated with a total dose of or > 6.5 mg/kg in one course of continuous dosing. Therapy with chlorambucil should be administered cautiously and at a reduced dosage in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

Chlorambucil has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Chlorambucil can severely suppress bone marrow function. It induces a slowly progressive lymphopenia and dose-related neutropenia. Thrombocytopenia and anemia may also occur. Irreversible bone marrow suppression has been reported and is associated with a total dose of or > 6.5 mg/kg in one course of continuous dosing. Therapy with chlorambucil should be administered cautiously and at a reduced dosage in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

The etrasimod in Velsipity has a major potential interaction with Cardiovascular Conditions and Disorders.

Etrasimod is contraindicated in patients who have experienced in the last 6 months myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, and Class III or IV heart failure. It is also contraindicated in patients with history of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker. Advice from a cardiologist should be sought if treatment is being considered in patients with significant QT prolongation, arrhythmias requiring treatment with Class Ia or Class II anti-arrhythmic drugs or QT prolonging drugs, unstable ischemic heart disease, Class I or III heart failure, history of cardiac arrest, cerebrovascular disease, uncontrolled hypertension, resting heart rate less than 50 beats per minute, symptomatic bradycardia, recurrent cardiogenic syncope, severe untreated sleep apnea, history of Mobitz type I second degree AV block, unless the patient has a functioning pacemaker.

Chlorambucil has a major potential interaction with Fever.

Chlorambucil can severely suppress bone marrow function. It induces a slowly progressive lymphopenia and dose-related neutropenia. Thrombocytopenia and anemia may also occur. Irreversible bone marrow suppression has been reported and is associated with a total dose of or > 6.5 mg/kg in one course of continuous dosing. Therapy with chlorambucil should be administered cautiously and at a reduced dosage in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

The etrasimod in Velsipity has a major potential interaction with Heart Disease.

Etrasimod is contraindicated in patients who have experienced in the last 6 months myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, and Class III or IV heart failure. It is also contraindicated in patients with history of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker. Advice from a cardiologist should be sought if treatment is being considered in patients with significant QT prolongation, arrhythmias requiring treatment with Class Ia or Class II anti-arrhythmic drugs or QT prolonging drugs, unstable ischemic heart disease, Class I or III heart failure, history of cardiac arrest, cerebrovascular disease, uncontrolled hypertension, resting heart rate less than 50 beats per minute, symptomatic bradycardia, recurrent cardiogenic syncope, severe untreated sleep apnea, history of Mobitz type I second degree AV block, unless the patient has a functioning pacemaker.

Chlorambucil has a major potential interaction with Infection.

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

The etrasimod in Velsipity has a moderate potential interaction with Infection.

Etrasimod increases the risk of infections as it decreases the peripheral lymphocyte counts. Treatment initiation should be delayed in patients with an active infection until the infection is resolved. Patients without a confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus, should be tested for antibodies before initiating treatment. Avoid the use of live attenuated vaccines during and for up to 5 weeks after treatment.

Chlorambucil has a moderate potential interaction with Liver Disease.

No formal studies have been conducted in patients with hepatic impairment. As chlorambucil is primarily metabolized in the liver, patients with hepatic impairment should be closely monitored for toxicity. A dose reduction may be considered in patients with hepatic impairment when treated with chlorambucil.

The etrasimod in Velsipity has a moderate potential interaction with Liver Disease.

Elevations of transaminases have been reported in patients receiving etrasimod. Additionally, this drug undergoes extensive hepatic metabolism, and its exposure was found increased in subjects with severe hepatic dysfunction (Child-Pugh C). The use of etrasimod is not recommended on these patients. No dosage adjustment is needed in mild to moderate hepatic dysfunction.

Chlorambucil has a moderate potential interaction with Pulmonary Impairment.

Interstitial pneumonitis and/or fibrosis have been reported during chlorambucil therapy. Pulmonary complications may not be reversible in all patients. Patients should be instructed to immediately report signs and symptoms of pulmonary dysfunction such as cough, dyspnea or congestion. Therapy with chlorambucil should be administered cautiously in patients with or predisposed to pulmonary dysfunction.

Chlorambucil has a moderate potential interaction with Seizures.

An increased risk of seizures has been reported in patients administered high pulse doses of chlorambucil and in children with nephrotic syndromes. Focal and/or generalized seizures have been reported rarely at daily therapeutic doses. Therapy with chlorambucil should be administered cautiously in patients with a history of seizure disorders or head trauma.

The etrasimod in Velsipity has a moderate potential interaction with Skin Cancer.

Cases of malignancies, including skin malignancies have been reported in patients treated with some sphingosine -1-receptor (S1P) receptor modulators. Skin examinations are recommended prior and during treatment in all patients, particularly in those with risk factors for skin cancer. Suspicious skin lesions should be promptly evaluated, and patients at increased risk should wear protective clothing and use sunscreen with high protection factor.

The etrasimod in Velsipity has a moderate potential interaction with Vaccination.

Etrasimod increases the risk of infections as it decreases the peripheral lymphocyte counts. Treatment initiation should be delayed in patients with an active infection until the infection is resolved. Patients without a confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus, should be tested for antibodies before initiating treatment. Avoid the use of live attenuated vaccines during and for up to 5 weeks after treatment.